-
-
-
-
-
-
-
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
-
-
-
-
-
-
-
Denali's Hunter syndrome drug shows promise in published study
-
-
-
-
-
-
-
Denali Therapeutics names new board member, chief medical officer
-
-
-
-
-
-
-
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
-
-
-
-
-
-
-
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
-
-
-
-
-
-
-
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
-
-
-
-
-
-
-
Denali Therapeutics Inc. (DNLI) Tops Q4 EPS by 4c
-
1,199,626 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

